跳转至内容
Merck
所有图片(1)

主要文件

ABK0014

Sigma-Aldrich

LuceBridge ELISA Kit from rabbit serum

登录查看公司和协议定价


About This Item

分類程式碼代碼:
41116158
NACRES:
NA.32

抗體表格

purified immunoglobulin

物種活性

human (IgG)

運輸包裝

wet ice

儲存溫度

2-8°C

一般說明

A Protein Conformational Array (PCA) in a sandwich ELISA format where the plate is coated with a panel of antibodies raised against peptides derived from the full length protein sequence of Ranibizumab. Taken individually, each of these antibodies is strongly antigenic to the peptide sequence that was used in its production. However, when these peptides are incorporated into a full length correctly folded protein, the antigenicity of many of them is masked by the three dimensional structure of the protein and only a limited number of the antibodies respond. The result is a histogram which can be likened to a ‘fingerprint′ for correctly folded Ranibizumab. For a Lucentis Biosimilar, if the protein is correctly folded and glycosylated, the ‘fingerprint′ will match that of Ranibizumab. If it is not correctly folded, previously masked peptide sequences will be exposed and will be recognized by the antibody made to that exposed sequence. In this way, changes in the ‘fingerprint′ generated by the ELISA will point out differences between the Biosimilar and authentic Ranibizumab.

應用

For research use only. Not for use in diagnostic procedures.

其他說明

ELISA kit contains 2 96-well microplates and all the components necessary to complete an ELISA test.

象形圖

Corrosion

訊號詞

Warning

危險聲明

危險分類

Eye Irrit. 2 - Met. Corr. 1 - Skin Irrit. 2

儲存類別代碼

8A - Combustible corrosive hazardous materials


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Xing Wang et al.
Frontiers in pharmacology, 4, 103-103 (2013-08-24)
Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of
Yuanli Song et al.
mAbs, 10(3), 397-405 (2018-01-10)
The elucidation of antibody higher order structure (HOS) is critical in therapeutic antibody development. Since HOS determines the protein bioactivity and chemo-physical properties, this knowledge can help to ensure that the safety and efficacy attributes are not compromised. Protein conformational
Biosimilar mAb in-process Sample Higher Order Structure Analysis with Protein Conformational Array ELISA.
Michael Davies, Gan Wang, Jian Gong, Guofeng Fu and Xing Wang
Pharmaceut. Res., 1-11 (2016)
Soon Kwan Jung et al.
mAbs, 6(5), 1163-1177 (2014-12-18)
Remsima (infliximab) was recently approved as the world's first biosimilar monoclonal antibody (mAb) in both the European Union and Korea. To achieve this, extensive physicochemical characterization of Remsima in relation to Remicade was conducted in order to demonstrate the highly

商品

Monoclonal antibodies (mAbs) are the fastest growing class of human therapeutics within the field of biologics, having predicted worldwide sales of $125 billion by 2020 based on current approval rates.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门